Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis
出版年份 2023 全文链接
标题
Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis
作者
关键词
-
出版物
BMC CANCER
Volume 23, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-11-06
DOI
10.1186/s12885-023-11572-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial
- (2022) Samuel A. Funt et al. JOURNAL OF CLINICAL ONCOLOGY
- Overcoming Chemotherapy Resistance in Germ Cell Tumors
- (2022) Zuzana Országhová et al. Biomedicines
- Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer
- (2022) Ahmet Murat Aydin et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Comparative cost‐effectiveness of neoadjuvant chemotherapy regimens for muscle‐invasive bladder cancer: Results according to VESPER data
- (2022) Daniel D. Joyce et al. CANCER
- TFAP2C Knockdown Sensitizes Bladder Cancer Cells to Cisplatin Treatment via Regulation of EGFR and NF-κB
- (2022) Ji Xing et al. Cancers
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration
- (2021) Praful Ravi et al. BJU INTERNATIONAL
- Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis
- (2021) Matteo Ferro et al. Frontiers in Oncology
- Three versus four cycles of neoadjuvant gemcitabine cisplatin for muscle invasive bladder cancer (MIBC).
- (2021) Catherine Kendall Major et al. JOURNAL OF CLINICAL ONCOLOGY
- Four versus Three Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathologic Response and Survival
- (2021) Hiten D. Patel et al. JOURNAL OF UROLOGY
- MP41-11 DEVIATIONS IN CYCLES OF NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER AND IMPLICATIONS FOR PATHOLOGIC RESPONSE AND SURVIVAL
- (2021) Enrique Blanco-Martinez et al. JOURNAL OF UROLOGY
- Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer
- (2021) David D'Andrea et al. JOURNAL OF UROLOGY
- Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis
- (2021) Doo Yong Chung et al. Cancers
- Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen
- (2021) Karin Holmsten et al. Bladder Cancer
- Downstaging of muscle invasive bladder cancer using neoadjuvant gemcitabine and cisplatin or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as single-regimens or switch therapy modalities
- (2020) Andrew T. Ruplin et al. Clinical Genitourinary Cancer
- Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
- (2020) Thomas W. Flaig et al. Journal of the National Comprehensive Cancer Network
- Fourier Transform Infrared Spectroscopy as a Cancer Screening and Diagnostic Tool: A Review and Prospects
- (2020) Kar-Yan Su et al. Cancers
- European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
- (2020) J. Alfred Witjes et al. EUROPEAN UROLOGY
- Treatment of muscle‐invasive and advanced bladder cancer in 2020
- (2020) Vaibhav G. Patel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities
- (2020) Gerda de Vries et al. CANCER TREATMENT REVIEWS
- Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses
- (2020) Christian Pfister et al. EUROPEAN UROLOGY
- Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
- (2020) Renu R Bahadoer et al. LANCET ONCOLOGY
- Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience
- (2019) Luca Boeri et al. WORLD JOURNAL OF UROLOGY
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer
- (2018) Gopa Iyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy
- (2018) Homayoun Zargar et al. JOURNAL OF UROLOGY
- Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer
- (2018) Charles C. Peyton et al. JAMA Oncology
- Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer
- (2018) Di (Maria) Jiang et al. Clinical Genitourinary Cancer
- Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits
- (2017) et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
- (2017) Sam S. Chang et al. JOURNAL OF UROLOGY
- Impact of suboptimal neoadjuvant chemotherapy on peri-operative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational study
- (2016) Nobuyuki Hinata et al. BJU INTERNATIONAL
- Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy
- (2016) Jinbo Chen et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis
- (2016) Ming Yin et al. ONCOLOGIST
- The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy
- (2016) William P. Parker et al. WORLD JOURNAL OF UROLOGY
- Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
- (2015) Matthew D. Galsky et al. CANCER
- Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
- (2015) Homayoun Zargar et al. EUROPEAN UROLOGY
- Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes
- (2015) Nilay M. Gandhi et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin
- (2015) Elisabeth E. Fransen van de Putte et al. WORLD JOURNAL OF UROLOGY
- Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Invasive Transitional and Squamous Cell Carcinoma of the Bladder: Effect on Survival and Bladder Preservation
- (2014) Hussein M. Khaled et al. Clinical Genitourinary Cancer
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses
- (2013) W.G. Melsen et al. CLINICAL MICROBIOLOGY AND INFECTION
- Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
- (2012) Nobuaki Matsubara et al. Asia-Pacific Journal of Clinical Oncology
- Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer
- (2011) Robert Rosenblatt et al. EUROPEAN UROLOGY
- Neoadjuvant Gemcitabine Plus Cisplatin for Muscle-invasive Bladder Cancer
- (2011) G. Kaneko et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial
- (2011) JOURNAL OF CLINICAL ONCOLOGY
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
- (2010) Andreas Stang EUROPEAN JOURNAL OF EPIDEMIOLOGY
- The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy
- (2009) Nicholas J. Hellenthal et al. BJU INTERNATIONAL
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started